By: Nichole Tucker From: targetedonc.com Neratinib plus capecitabine improved progression-free survival and time to intervention for central nervous system disease in patients with previously treated HER2-positive metastatic breast cancer compared with lapatinib plus capecitabine, results from the phase 3 NALA trial show. The combination of neratinib (Nerlynx) and capecitabine (Xeloda) improved progression-free survival (PFS) and time to intervention for central …
-
-
The Gift of Discussing Your Family Medical History as a Breast Cancer Survivor
-
Thanksgiving Day Gratitude as a Breast Cancer Survivor
-
Keeping My Word in the World of Breast Cancer
-
A Hero Moment on Veterans Day from this Breast Cancer Survivor
-
Why This Breast Cancer Survivor Will Enjoy Today for Today
